Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Beamion LUNG-1 zongertinib monotherapy in HER2-aberrant advanced solid tumors and HER2-mutant NSCLC
jRCT2031210165Phase 1Active, not recruiting
- Sponsor
- Boehringer Ingelheim
- Start
- Jul 2021
- Modality
- Small Molecules
01
Overview
Phase 1, open-label trial of zongertinib in Nonhematologic neoplasms and non-small cell lung cancer (NSCLC) (2 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Maximum tolerated dose, Dose-limiting toxicities during MTD evaluation period and 1 more. Started Jul 2021; status: active, not recruiting.
02
Drugs
zongertinib
03
Conditions
Nonhematologic neoplasmsnon-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCT2031210165.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031210165.